Evidence map›Paper›PMID 15890937›Full record

ArticleJournal of virology2005

Strain-specific T-cell suppression and protective immunity in patients with chronic hepatitis C virus infection.

Kazushi Sugimoto, David E Kaplan, Fusao Ikeda, Jin Ding, Jonathan Schwartz, Frederick A Nunes, Harvey J Alter, Kyong-Mi Chang

Abstract readComparative Study
In one paragraph

Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Adaptive immunity to the hepatitis C virus.Advances in virus research · 2010
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kazushi SugimotoDepartment of Medicine, GI Division, University of Pennsylvania, and Philadelphia VAMC, A212 Medical Research, PVAMC, University and Woodland Avenues, Philadelphia, PA 19104, USA.
David E Kaplan
Fusao Ikeda
Jin Ding
Jonathan Schwartz
Frederick A Nunes
Harvey J Alter
Kyong-Mi Chang

Funding

TRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Ken Hashigiwa Cadwell · 1997 to 2026
$32.5M
ZDV VS ZDV + DDL VS ZDV + DDL + NVP IN ASYMPTOMATIC HIV PATIENTSM01RR000040 · NCRR · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 1985 to 2006
$21.1M
CELLULAR IMMUNITY--OUTCOME HEPATITIS C VIRUS INFECTIONR01AI047519 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI CHANG, KYONG-MI · 1999 to 2010
$3.1M
ALCOHOL/CELLULAR IMMUNITY IN HCV AND HIV INFECTIONR01AA012849 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI CHANG, KYONG-MI · 2000 to 2004
$1.9M
Study Of Anti-hepatitis C Virus Positive Blood DonorsZ01CL002068 · CLC · CLINICAL CENTER · PI ALTER, HARVEY J · 1992 to 2008
$274k
A Prospective Study Of Anti-hepatitis C Virus Positive Blood DonorsZIACL002068 · CLC · CLINICAL CENTER · PI DE GIORGI, VALERIA · 2009 to 2025
$0k
NCRR NIH HHS M01 RR000040NCRR NIH HHS M01-RR00040NIAAA NIH HHS AA12849NIAAA NIH HHS R01 AA012849NIAID NIH HHS AI47519NIAID NIH HHS R01 AI047519NIDDK NIH HHS P30 DK050306NIDDK NIH HHS P30DK50306PHS HHS T32 07066
6 · The paper itself

Abstract

Hepatitis C virus (HCV) frequently persists with an apparently ineffective antiviral T-cell response. We hypothesized that some patients may be exposed to multiple HCV subtypes and that strain-specific T cells could contribute to the viral dynamics in this setting. To test this hypothesis, CD4 T-cell responses to three genotype 1a-derived HCV antigens and HCV antibody serotype were examined in chronically HCV infected (genotypes 1a, 1b, 2, 3, and 4) and spontaneously HCV recovered subjects. Consistent with multiple HCV exposure, 63% of patients infected with genotypes 2 to 4 (genotypes 2-4) and 36% of those infected with genotype 1b displayed CD4 T-cell responses to 1a-derived HCV antigens, while 29% of genotype 2-4-infected patients showed serotype responses to genotype 1. Detection of 1a-specific T cells in patients without active 1a infection suggested prior self-limited 1a infection with T-cell-mediated protection from 1a but not from non-1a viruses. Remarkably, CD4 T-cell responses to 1a-derived HCV antigens were weakest in patients with homologous 1a infection and greater in non-1a-infected patients: proportions of patients responding were 19% (1a), 36% (1b), and 63% (2-4) (P = 0.0006). Increased 1a-specific CD4 T-cell responsiveness in non-1a-infected patients was not due to increased immunogenicity or cross-reactivity of non-1a viruses but directly related to sequence divergence. We conclude that the T-cell response to the circulating virus is either suppressed or not induced in a strain-specific manner in chronically HCV infected patients and that, despite their ability to clear one HCV strain, patients may be reinfected with a heterologous strain that can then persist. These findings provide new insights into host-virus interactions in HCV infection that have implications for vaccine development.

Indexed as

Case-Control StudiesGenotypeHepacivirusHepatitis C, ChronicHumansImmune ToleranceIn Vitro TechniquesLymphocyte ActivationMiddle AgedModels, ImmunologicalSerotypingSpecies SpecificityT-Lymphocytes

Identifiers

PMID15890937
PMCPMC1112102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.